Bleeding & Clotting Disorders Institute
Bleeding & Clotting Disorders Institute reported $18.3 million in revenue and $17.0 million in expenses for the fiscal year ending June 30, 2025. Of every $100 it spent, $70.97 went to program services, $29.03 to management and general costs and $0.00 to fundraising. Its largest source of revenue was program service revenue such as fees, sales and contracts: 4.5% of the total. The highest compensation it reported for one person was $825,362 (CEO/CMO, SECRETARY). 8 people received more than $100,000 in reportable compensation. Revenue fell 42% between FY2020 and FY2025. Source: Form 990, FY2025.
Where $100 of spending went
The fiscal year ending June 30, 2025 · Form 990, Part IX, line 25 · total expenses $17MFor context, the median across 5,634 covered health care charities: $86.19 programs, $13.81 management, $0.00 fundraising (medians computed separately, so they may not sum to $100).
Where $100 of revenue came from
The fiscal year ending June 30, 2025 · Form 990, Part VIII · total revenue $18MThe 990 scorecard · same measures for every charity, no grades
| Measure | FY2025 | Median |
|---|---|---|
| Program services Part IX 25(B) ÷ 25(A) | 71.0% | 85.6% |
| Management & general Part IX 25(C) ÷ 25(A) | 29.0% | 13.7% |
| Fundraising Part IX 25(D) ÷ 25(A) | 0.0% | 0.0% |
| Fundraising cost per $1 of contributions Part IX 25(D) ÷ Part VIII 1h | Not reported | $0.00 |
| Contributions & grants share of revenue Part VIII 1h ÷ 12 | 0.6% | 1.3% |
| Government grants share of revenue Part VIII 1e ÷ 12 | 0.0% | 0.1% |
| Program service revenue share Part VIII 2g ÷ 12 | 4.5% | 93.7% |
| Highest reported compensation Part VII-A, columns D–F | $825,362 | $975,831 |
| Highest compensation as share of expenses Part VII-A ÷ Part IX 25(A) | 4.86% | 1.34% |
| People paid over $100,000 Part VII, line 2 | 8 | 27 |
| Net assets, in months of expenses Part X 33(B) ÷ monthly expenses | 21.1 | 6.6 |
| Independent voting board members Part VI 1a–1b | 6 of 7 | 88.9% |
A median is context, not a target: hospitals, universities, food banks and grantmakers spend in very different ways. What these measures can and can't tell you.
What the money paid for, in its own words
FY2025 · Form 990, Part III · the three largest programs by expenseHighest reported compensation
FY2025 · Form 990, Part VII, Section A · roles as filed; names are in the filing, not here| Role | From this org | From related orgs | Other | Total |
|---|---|---|---|---|
| CEO/CMO, SECRETARY Director/trustee, officer, 40.00 hrs/week | $821,900 | $0 | $3,462 | $825,362 |
| CFO/COO Director/trustee, officer, 40.00 hrs/week | $293,534 | $0 | $56,930 | $350,464 |
| ASSOCIATE MEDICAL DIRECTOR Key employee, 40.00 hrs/week | $247,465 | $0 | $55,018 | $302,483 |
| PHARMACIST IN CHARGE Highest compensated employee, 40.00 hrs/week | $183,647 | $0 | $62,881 | $246,528 |
| STAFF HEMATOLOGIST Highest compensated employee, 40.00 hrs/week | $194,547 | $0 | $49,875 | $244,422 |
| NURSE PRACTITIONER Highest compensated employee, 40.00 hrs/week | $152,839 | $0 | $57,623 | $210,462 |
| APP SUPERVISOR Highest compensated employee, 40.00 hrs/week | $165,601 | $0 | $26,792 | $192,393 |
| STAFF PHYSICIAN Highest compensated employee, 40.00 hrs/week | $146,988 | $0 | $45,127 | $192,115 |
8 people received more than $100,000 in reportable compensation from Bleeding & Clotting Disorders Institute (Part VII, line 2). Compensation of current officers, directors and key employees totaled $2.0M (Part IX, line 5).
6 years of filings
Form 990, Parts I, VII, IX and X · each row is that year's own filing, linkedGovernance answers, as filed
FY2025 · the organization's own yes/no answers; explanations, if any, are in Schedule O of the filing · what each means- Voting board members, and how many are independent Part VI, lines 1a–1b7 · 6 independent
- Audited financial statements Part XII 2bYes
- Conflict-of-interest policy Part VI 12aYes
- Whistleblower policy Part VI 13Yes
- Document retention policy Part VI 14Yes
- Independent process for top executive pay Part VI 15aYes
- Board given the 990 before filing Part VI 11aYes
- Family or business ties among insiders Part VI 2No
- Aware of a significant diversion of assets Part VI 5No
- Excess benefit transaction with an insider Part IV 25aNo
- Loans to or from insiders outstanding Part IV 26No
- Lobbying, or a 501(h) election in effect Part IV 4No
- Over $15,000 of professional fundraising services Part IV 18No
- Over $10,000 of activity outside the U.S. Part IV 14bNo
- Employees Part I, line 593
- Volunteers Part I, line 680
Largest outside contractors
FY2025 · Form 990, Part VII, Section B · businesses onlyIndividuals listed as contractors are left out. 2 contractors were paid more than $100,000 in all.
Private foundation grants it received
3 private foundations reported grants to Bleeding & Clotting Disorders Institute totaling $207K on their tax year 2023 Form 990-PF returns. See which foundations, on WHOFUNDS.
Source: WHOFUNDS open grant graph, matched from Form 990-PF Part XV.
Correct a figure or respond
Every number above is copied from Bleeding & Clotting Disorders Institute's own Form 990. If one doesn't match the filing, that's our error and we'll fix it. If you work for Bleeding & Clotting Disorders Institute, you can publish a response that is linked from this page.
Share or embed this breakdown
Of every $100 Bleeding & Clotting Disorders Institute spent in FY2025, $70.97 went to programs. The full breakdown, from its IRS Form 990:
Embed on your site
Similar-sized charities in this cause
- Mercy Restorative Care HospitalPlano, TX · revenue $18M · programs 81.0% · FY2025
- Beacon Health FoundationSouth Bend, IN · revenue $18M · programs 68.7% · 2024
- Baystate HealthSpringfield, MA · revenue $18M · programs 70.8% · FY2025
- Make-A-Wish Foundation of Southern FloridaMiami, FL · revenue $18M · programs 65.7% · FY2025
- Stony Brook Urology University Faculty Practice CorporationStony Brook, NY · revenue $18M · programs 89.1% · FY2025
Questions people ask
How much of Bleeding & Clotting Disorders Institute's spending goes to programs?
In the fiscal year ending June 30, 2025, Bleeding & Clotting Disorders Institute reported that 71.0% of its $17.0 million in expenses went to program services, 29.0% to management and general and 0.0% to fundraising (Form 990, Part IX).
How much does Bleeding & Clotting Disorders Institute pay its top executive?
The largest total compensation Bleeding & Clotting Disorders Institute reported for one person in the fiscal year ending June 30, 2025 was $825,362, for the role of CEO/CMO, SECRETARY (Form 990, Part VII, including compensation from related organizations and other compensation).
Where does Bleeding & Clotting Disorders Institute get its money?
Of $18.3 million in revenue in the fiscal year ending June 30, 2025, 0.6% came from contributions and grants and 4.5% from program service revenue (Form 990, Part VIII).
Is Bleeding & Clotting Disorders Institute a registered charity?
The IRS lists EIN 27-2050459 as a 501(c)(3) organization (publicly supported organization (509(a)(2))), and its records show contributions as tax-deductible. Form 990 filings on record here cover tax years 2019, 2020, 2021, 2022, 2023, 2024. A filing shows what the organization reported; it doesn't by itself show whether a program works.
Sources
- FY2025: Form 990 for the fiscal year ending June 30, 2025, object 202630229349300418 · read the filing · XML
- FY2024: Form 990 for the fiscal year ending June 30, 2024, object 202500659349301300 · read the filing
- FY2023: Form 990 for the fiscal year ending June 30, 2023, object 202411039349302006 · read the filing
- FY2022: Form 990 for the fiscal year ending June 30, 2022, object 202331359349303798 · read the filing
- FY2021: Form 990 for the fiscal year ending June 30, 2021, object 202200569349300215 · read the filing
- FY2020: Form 990 for the fiscal year ending June 30, 2020, object 202100569349301900 · read the filing
All filings for EIN 27-2050459: ProPublica Nonprofit Explorer · IRS Tax Exempt Organization Search. Figures are as the organization reported them; we have not audited them.